Trial Profile
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ALT 801 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Altor BioScience Corporation
- 13 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 08 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
- 08 Dec 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.